2 Stocks That Are Rising Due to the Tragic Orlando Massacre; Plus 3 Other Hot Stocks

Page 1 of 2

After briefly rallying into the green, the S&P 500 and Dow Jones are again falling. As of noon, the Dow is down by 64 points, while the S&P 500 is off by over 0.4% and the Nasdaq is 0.68% in the red. Among the stocks still in the green today are Twitter Inc (NYSE:TWTR), Eleven Biotherapeutics Inc (NASDAQ:EBIO), Smith & Wesson Holding Corp (NASDAQ:SWHC), COPsync Inc (NASDAQ:COYN), and Netflix, Inc. (NASDAQ:NFLX). Let’s examine why traders are maintaining their positivity for these equities today and see what the smart money in our database thinks of each stock.

Our backtests that covered the period between 1999 and 2012, showed that following the 15 most popular small-caps among hedge funds can help a retail investor beat the market by an average of 95 basis points per month (see the details here).

Netflix, Inc. (NASDAQ:NFLX), homepage, streaming, Ipad, video, tv, tablet, app, watch,

Twin Design / Shutterstock.com

Twitter a Beneficiary of Social Media Sector Buzz

Twitter Inc (NYSE:TWTR) is 6% higher today after Microsoft Corporation (NASDAQ:MSFT) announced it is buying LinkedIn Corp (NYSE:LNKD) for $26.2 billion, or $196 per share. Although Twitter Inc (NYSE:TWTR) doesn’t compete against LinkedIn, it is also a social media company and some investors think Microsoft’s purchase could make a potential sale of Twitter more likely. If Twitter is sold to another company, it will likely be at a big premium to the spot price. Of the 766 elite funds that we track, 27 owned long positions in Twitter Inc (NYSE:TWTR) valued at $403.17 million, which accounted for 3.50% of the stock’s float on March 31.

Follow Twitter Inc. (NYSE:TWTR)

Eleven Biotherapeutics Up on Development Deal

Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares have surged by almost 50% after the nano-cap entered into an exclusive license agreement with Roche concerning its IL-6 antagonist antibody technology. Under the terms of the deal, Eleven Biotherapeutics will receive $7.5 million in upfront payments, future milestone payments of up to $262.5 million, and royalties in exchange for granting an exclusive worldwide license to Roche to develop and commercialize EBI-031. The treatment, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, is currently being developed for the potential treatment of ocular diseases. The deal also includes all other IL-6 antagonist antibody technology owned by Eleven Biotherapeutics. Two funds in our database owned shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO) at the end of the first quarter.

Follow Carisma Therapeutics Inc. (NASDAQ:CARM)

On the next page we examine Smith & Wesson, COPsync, and Netflix are on the rise today.

Page 1 of 2